Skip to main content
Top
Published in: Intensive Care Medicine 9/2017

01-09-2017 | What's New in Intensive Care

The research agenda in VAP/HAP: next steps

Authors: Michael S. Niederman, Ignacio Martin-Loeches, Antoni Torres

Published in: Intensive Care Medicine | Issue 9/2017

Login to get access

Excerpt

In the coming decade, ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) will continue to be major infections in the intensive care unit (ICU). While prevention efforts may reduce the frequency of these infections, we do not believe that “zero VAP”, which is a common goal in the USA, has or will be achieved, as evidenced by continued antibiotic use for nosocomial respiratory infections [1]. In Europe, the degree of preventable VAP has been estimated to be approximately 50%, so many episodes will still be present, in spite of the use of ventilator bundles [2]. In the coming decade, we anticipate the need for better epidemiologic and diagnostic tools that will inform us about the true incidence of these infections and the impact of specific prevention strategies. For epidemiologic purposes, the concept of ventilator-associated events (VAE), used by some in the USA, has not gained traction in Europe and it seems unlikely to become a valued concept [3]. Recently, a systematic review and meta-analysis examined 61,489 patients receiving mechanical ventilation in eight countries and found that the pooled sensitivity and positive predictive value of each VAE type for VAP detection did not exceed 50%, reflecting that VAE surveillance does not accurately detect cases of traditional VAP [3]. The clinical management and importance of the ventilator-associated lower respiratory tract infections (VA-LRTI) concept also need clarification. A multicentre, prospective, observational study found improved outcomes with the use of appropriate antibiotic treatment in VA-LRTI (including ventilator-associated tracheobronchitis, or VAT) [4]. Future studies are needed to see if VAT is an appropriate illness for routine antibiotic therapy, or whether only certain specific VAT needs antibiotic treatment. One area not covered by VA-LRTI is pneumonia in non-ventilated patients, and the topic of HAP requires more study to clarify its true incidence and bacteriology (possibly with quantitative culture methods) and to determine if the current assumptions, that the bacteriology parallels that of VAP, are in fact accurate. …
Literature
1.
go back to reference Matar DS, Pham JC, Louis TA, Berenholtz SM (2013) Achieving and sustaining ventilator-associated pneumonia-free time among intensive care units (ICUs): evidence from the Keystone ICU Quality Improvement Collaborative. Infect Control Hosp Epidemiol 34:740–743. doi:10.1086/670989 CrossRefPubMed Matar DS, Pham JC, Louis TA, Berenholtz SM (2013) Achieving and sustaining ventilator-associated pneumonia-free time among intensive care units (ICUs): evidence from the Keystone ICU Quality Improvement Collaborative. Infect Control Hosp Epidemiol 34:740–743. doi:10.​1086/​670989 CrossRefPubMed
2.
go back to reference Lambert ML, Silversmit G, Savey A, Palomar M, Hiesmayr M, Agodi A et al (2014) Preventable proportion of severe infections acquired in intensive care units: case-mix adjusted estimations from patient-based surveillance data. Infect Control Hosp Epidemiol 35:494–501. doi:10.1086/675824 CrossRefPubMed Lambert ML, Silversmit G, Savey A, Palomar M, Hiesmayr M, Agodi A et al (2014) Preventable proportion of severe infections acquired in intensive care units: case-mix adjusted estimations from patient-based surveillance data. Infect Control Hosp Epidemiol 35:494–501. doi:10.​1086/​675824 CrossRefPubMed
7.
go back to reference Martin-Loeches I, Deja M, Koulenti D, Dimopoulos G, Marsh B, Torres A, Niederman MS, Rello J, EU-VAP Study Investigators (2013) Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 39:672–681. doi:10.1007/s00134-012-2808-5 CrossRefPubMed Martin-Loeches I, Deja M, Koulenti D, Dimopoulos G, Marsh B, Torres A, Niederman MS, Rello J, EU-VAP Study Investigators (2013) Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 39:672–681. doi:10.​1007/​s00134-012-2808-5 CrossRefPubMed
10.
go back to reference Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E et al (2014) Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 33:1861–1867. doi:10.1007/s10096-014-2156-1 CrossRefPubMed Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E et al (2014) Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 33:1861–1867. doi:10.​1007/​s10096-014-2156-1 CrossRefPubMed
11.
go back to reference Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61–e111. doi:10.1093/cid/ciw353 CrossRefPubMed Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61–e111. doi:10.​1093/​cid/​ciw353 CrossRefPubMed
12.
go back to reference Planquette B, Timsit JF, Misset BY, Schwebel C, Azoulay E, Adrie C et al (2013) Pseudomonas aeruginosa ventilator-associated pneumonia. Predictive factors of treatment failure. Am J Respir Crit Care Med 188:69–76. doi:10.1164/rccm.201210-1897OC CrossRefPubMed Planquette B, Timsit JF, Misset BY, Schwebel C, Azoulay E, Adrie C et al (2013) Pseudomonas aeruginosa ventilator-associated pneumonia. Predictive factors of treatment failure. Am J Respir Crit Care Med 188:69–76. doi:10.​1164/​rccm.​201210-1897OC CrossRefPubMed
13.
go back to reference Niederman MS, Chastre J, Corkery K et al (2012) BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 38:263–271. doi:10.1007/s00134-011-2420-0 CrossRefPubMed Niederman MS, Chastre J, Corkery K et al (2012) BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 38:263–271. doi:10.​1007/​s00134-011-2420-0 CrossRefPubMed
14.
15.
go back to reference De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M et al (2014) Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med 40:1340–1351. doi:10.1007/s00134-014-3403-8 CrossRefPubMed De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M et al (2014) Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med 40:1340–1351. doi:10.​1007/​s00134-014-3403-8 CrossRefPubMed
Metadata
Title
The research agenda in VAP/HAP: next steps
Authors
Michael S. Niederman
Ignacio Martin-Loeches
Antoni Torres
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 9/2017
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-017-4695-2

Other articles of this Issue 9/2017

Intensive Care Medicine 9/2017 Go to the issue